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The complement system plays a central role in immune defense against Streptococcus
pneumoniae. In order to evade complement attack, pneumococci have evolved a
number of mechanisms that limit complement mediated opsonization and subsequent
phagocytosis. This review focuses on the strategies employed by pneumococci to
circumvent complement mediated immunity, both in vitro and in vivo. At last, since
many of the proteins involved in interactions with complement components are vaccine
candidates in different stages of validation, we explore the use of these antigens alone
or in combination, as potential vaccine approaches that aim at elimination or drastic
reduction in the ability of this bacterium to evade complement.
Keywords: complement system, Streptococcus pneumoniae, virulence factors pneumococcal surface proteins,
pneumococcal moonlighting proteins, protein-based vaccines
INTRODUCTION
The complement system is an important mechanism in human immunity, with more than thirty
proteins produced in soluble phase by the liver or expressed in cell surfaces [reviewed in (Ritchie
et al., 2002; Dunkelberger and Song, 2010; Merle et al., 2015a)]. This system comprises a set of
recognition molecules present in the plasma and interstitial fluids that are quickly activated in
response to pathogens such as bacteria, yeast and virus, as well as infected cells and damaged tissues
(Dunkelberger and Song, 2010; Ehrnthaller et al., 2011). Complement activation is triggered by
serine protease domains present in components that become active and cleave the next protein in
a cascade-like manner [reviewed in (Ehrnthaller et al., 2011; Merle et al., 2015a)]. The proteolytic
cleavage steps generate fragments that bind to the microbial surfaces thereby acting as opsonins,
promoting a more efficient phagocytosis and releasing peptides into the bloodstream, which are
able to induce inflammatory responses [reviewed in (Merle et al., 2015b)]. Complement activation
also promotes assembly of the membrane attack complex (MAC), which is capable of forming pores
on membranes, causing osmotic lysis (Esser, 1994; Ritchie et al., 2002).
Streptococcus pneumoniae is a common colonizer of the human nasopharynx and is usually
asymptomatic; however, in susceptible hosts it can invade other niches, causing otitis media,
conjunctivitis, pneumonia, meningitis, and septicaemia (Kadioglu et al., 2008). The immune
response against pneumococcal infections is highly supported by complement activities such as
opsonization and activation of inflammatory responses (Janoff et al., 1999; Jarva et al., 2003).
In order to evade the anti-bacterial effects of complement, pneumococci have developed many
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virulence factors that impair complement activity, thus
contributing to bacterial evasion from the immune system
(Jarva et al., 2003).
The current prophylaxis against pneumococcal diseases is
based on polysaccharide vaccines (alone or conjugated to protein
carriers), which have proven to be effective against invasive
disease (Braido et al., 2008). However, high production costs
and a reduced number of polysaccharide serotypes included
in the formulations (a limitation of the conjugation process)
have hampered the implementation of these vaccines in lower
income countries, which are greatly affected by pneumococcal
diseases (Croney et al., 2013). This scenario encourages the efforts
to find alternative vaccines that can offer higher coverage at
a reduced cost, as well as increasing protection against non-
invasive disease (Moffitt and Malley, 2011; Darrieux et al., 2015).
Based on these considerations and the role of bacterial proteins
in complement attack, many proteins have been evaluated as
vaccines in animal infection models, with encouraging outcomes.
The employment of proteins that have roles in the inhibition
of complement as vaccine antigens could promote the blockage
of anti-complement abilities of pneumococci and result in more
effective opsonophagocytosis. In addition, the combination of
proteins may trigger broader, more effective immune responses
compared to the use of one antigen alone. Therefore, the
present review discusses the role of pneumococcal proteins
in complement evasion, as well as the potential of using
combinations of these proteins as pneumococcal vaccines.
CONTRIBUTION OF THE COMPLEMENT
SYSTEM TO HOST IMMUNITY AGAINST
PNEUMOCOCCI
As a classic extracellular bacterium, antibody-enhanced
complement-mediated phagocytosis is an essential mechanism
of pneumococcal clearance from the host (Brown et al., 1983;
Paterson and Orihuela, 2010). Infection with S. pneumoniae
activates all three pathways of the Complement System
(Figure 1A), which converge in the formation of C3b and
generate other molecules involved in opsonophagocytosis and
activation of inflammatory responses (Supplementary Table 1).
The classical pathway is activated by specific antibodies and
by recognition of cell wall phosphorylcholine by natural IgM
(Brown et al., 2002). In the absence of antibodies, SIGN-
R1, a transmembrane C-type lectin expressed by macrophages,
recognizes carbohydrates on the pneumococcal surface and binds
to C1q (Kang et al., 2006). Moreover, polymeric IgA molecules
can activate complement on the pneumococcal surface (Janoff
et al., 1999). More recently, it has been demonstrated that
C1q acts as a bridge between pneumococci and host tissues
in vitro. C1q bound to pneumococcal surface proteins through
its C-terminal globular head region, in an antibody-independent
fashion. Furthermore, C1q bound to pneumococci was able
to interact with respiratory cells (Agarwal et al., 2013a) –
possibly through glycosaminoglycan receptors (GAG) on their
surface (Almeda et al., 1983) – promoting bacterial adherence
and invasion (Agarwal et al., 2013a). The consequences of this
interaction have not been investigated in vivo, although C1q
bound simultaneously to pneumococci and host cells is still
able to promote complement activation on pneumococcal cells
(Agarwal et al., 2013a).
After recognition, the C1 complex becomes active and cleaves
C4 into C4a – released to the soluble phase – and C4b, which
remains attached to the bacterial surface; C2 binds to C4b and is
split up by C1s yielding C2a – that remains bound to C4b – and
C2b. The C4b2a, termed C3 convertase of the classical pathway,
is able to cleave plasmatic C3 into C3a (anaphylatoxin) and C3b.
C3b plays a pivotal role in the complement system; it is required
to form the C5 convertase complex, when additional C3b binds
to C3 convertase [reviewed in (Ehrnthaller et al., 2011; Merle
et al., 2015a)]. Formation of C5 convertase marks the late stage
of complement activation, which culminates with the assembly
of MAC [reviewed in (Esser, 1994; Ehrnthaller et al., 2011)]. As
a Gram-positive pathogen, the thick peptidoglycan layer on the
pneumococcal cell wall limits the effects of MAC attack (Jarva
et al., 2003); yet, the complement opsonic and pro-inflammatory
functions are essential for the control of pneumococcal infections
(Brown et al., 1983; Paterson and Mitchell, 2006), facilitating
bacterial phagocytosis and clearance. In that matter, C3b attached
to microbial surfaces may act as an opsonin, or generate the
amplification loop, where C3b associates with Bb, a protein of
alternative pathway, promoting more C3 convertase formation
[reviewed in (Ehrnthaller et al., 2011; Merle et al., 2015a)].
The importance of the classical pathway for immunity
against pneumococci is further supported by the observation
that deficiency in classical complement components such as
C1q, C4 and C2 is associated with recurrent and severe
pneumococcal infections (Rupprecht et al., 2007; Yuste et al.,
2008). Similarly, mouse models of complement deficiency (either
by genetic manipulation or transient depletion) reveal an
increased susceptibility to pneumococcal sepsis (Brown et al.,
2002).
The lectin pathway is initiated when Mannose-binding lectin
(MBL), collectin-10, collectin-11, or ficolins-1, 2, or 3 bind to
target surfaces and interact with the serine proteases MASP-
1, 2, and 3. Upon target binding, MASP-1 can self-activate
and is required for activation of MASP-2. MASP-2 then cleaves
C4 and both enzymes cleave C2, generating the classical C3
convertase (C4b2a). A third serine protease, MASP-3, is able
to activate pro-Factor D [pro-FD) in the resting human blood,
favoring alternative complement pathway activation [reviewed in
(Dobo et al., 2016)]. The lectin pathway plays a less crucial but
still important role in complement-mediated immunity against
pneumococci (Ali et al., 2012; Garcia-Laorden et al., 2013). While
a previous report found no clear role for MBL in pneumococcal
infections (Brown et al., 2002), more recent studies found an
important contribution for the lectin pathway in mice that do
not express ficolins (Endo et al., 2012) or MASP-2 (Ali et al.,
2012), which showed an increased susceptibility to pneumococcal
infections and a reduced opsonizing capacity in non-immune
hosts (Ali et al., 2012; Endo et al., 2012). Different components
on the pneumococcal surface interact with lectins: L-ficolin
binds to the capsular polysaccharides 11A, 11D, and 11F, and
to phosphorylcholine residues (ChoP) on the bacterial cell wall,
Frontiers in Microbiology | www.frontiersin.org 2 February 2017 | Volume 8 | Article 224
fmicb-08-00224 February 16, 2017 Time: 16:38 # 3
Andre et al. Complement Evasion by Pneumococcal Virulence Factors
FIGURE 1 | (A) Complement System activation pathways. The classical pathway is activated by binding of C1q molecules to IgM or IgG. C1s cleaves C4 into C4a
and C4b, further degrading C2 when bound with C4b, forming C2b (free molecule) and C2a, which remains bound to C4b forming C4bC2a (C3 convertase of the
classical pathway). The lectin pathway is activated in a similar fashion, by binding of MBL molecule to mannose or other sugars on microbial surfaces. It can also be
initiated by ficolins or collectins. Upon target binding, MASP-1 autoactivates first, and then it activates MASP-2. MASP-2 then cleaves C4 and both enzymes cleave
C2, generating the classical C3 convertase (C4b2a). A third serine protease, MASP-3, is able to activate pro-Factor D (pro-FD) in the resting human blood, favoring
alternative complement pathway activation. The Alternative pathway is activated continuously by spontaneous hydrolysis of C3 into C3 (H2O); FB binds to this
molecule and is split up by FD, yielding Ba and Bb that remains bound to form C3 (H2O)Bb (the initial alternative pathway C3 convertase). This convertase is able to
cleave C3 in the blood, generating C3a and C3b, which attaches to the activating surface and recruits FB. Binding of C3b with the cleavage product of FB, Bb,
(Continued)
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FIGURE 1 | (Continued)
generates the second C3convertase of the alternative pathway, C3bBb. The amplification loop is initiated when plasmatic C3 is cleaved by C3 convertase from all
three pathways yielding more C3b, which may lead to more convertase or promote microbial opsonization. The C5 convertase is formed by association of one C3b
molecule to the C3 convertase (in all pathways). This aggregate cleaves C5 molecules into C5a (anaphylatoxin) and C5b, which is the platform for C6 binding. Following
the cascade, C7, C8, and C9 (16–18 units) molecules bind to the activated surface to form the membrane attack complex. (B) Pneumococcal virulence factors act on
different points of the complement cascades. Each pneumococcal antigen is depicted in relation to the complement components they interact with. PLY, GDAPH and
PepO promote activation and depletion of complement components. PspA inhibits activation of both classical (CP) and alternative pathways (AP) C3 convertases;
LytA inhibits classical pathway activation. PspC, PepO, Eno, and LytA undermine CP C3 convertase formation. PspC, Phts, LytA, and Tuf impair AP C3 convertase
formation, as well as the amplification loop. PGK and PspC inhibit MAC assembly. NanA, BgaA, and StrH remove sialic acids from complement components, limiting
complement mediated phagocytosis; they inhibit AP, but the mechanism responsible for the inhibition is not clear. The pneumococcal moonlighting proteins (MP) have
indirect influence on complement through their interaction with PLG and consequent degradation of complement components.
while M-ficolin interacts with N-acetylmannosamine in capsular
types 19B and 19C (Kjaer et al., 2013). As a result of this
recognition, the complement proteolytic cascade continues as
described for the classical pathway [reviewed in (Merle et al.,
2015a)].
As observed for the classical pathway, genetic deficiency in
MBL is related to an increased susceptibility to pneumococcal
disease (Roy et al., 2002). A meta-analysis on human studies
suggested that MBL deficiency may be associated with
susceptibility to invasive pneumococcal disease (Garcia-Laorden
et al., 2013). This was confirmed by Brouwer et al. (2013) in a
cohort study, showing that MBL deficiency was associated with
a considerable increase in susceptibility to meningitis caused by
S. pneumoniae (Brouwer et al., 2013).
The alternative pathway is initiated when C3 (H2O) – resulting
from spontaneous hydrolysis of C3 (Pangburn et al., 1981) –
is recognized by factor B (FB) which is then cleaved in factor
Ba and factor Bb by factor D (FD); Bb remains attached to
C3 (H2O), forming the soluble phase C3 convertase of the
alternative pathway. This convertase is able to cleave C3 in
the blood, generating C3a and C3b; if C3b is formed close
enough to the cell membrane, it will covalently attach to that
surface and, because it is structurally similar to C3 (H2O), it will
recruit FB and the cascade will proceed on the activating surface
(Pangburn et al., 1983). The activation cascade triggered by the
alternative pathway was found to be related to the density of C3b
deposited on the bacterial surface (Jarva et al., 2003), which can
be translated in more opsonization of pneumococci. Also, the
observation that knockout mice for alternative pathway proteins,
such as factor B and factor D, are more susceptible pneumococcal
infections by strains which lack important virulence factors
strongly suggests that this complement pathway contributes to
pneumococcal clearance by the host. This will be discussed in
more detail further.
Other molecules – including C-reactive protein (CRP)
(Biro et al., 2007; Gang et al., 2015), surfactant protein A (S-PA)
(Watford et al., 2001; Madhukaran et al., 2015), serum amyloid P
(SAP) (Yuste et al., 2007) and molecules of the coagulation
cascade (Muhlfelder et al., 1979; Sims et al., 1988; Amara
et al., 2010; Rayes et al., 2014; Kim et al., 2015) can
activate complement. Particularly CRP and SAP recognize
S. pneumoniae and induce complement activation on this
bacterium (Yuste et al., 2007; Gang et al., 2015). Both have
collagen binding sites which promote binding to C1q and are
able to interact with polysaccharides (PS), lipopolysaccharides
(LPS), and phosphocholine (PCh) on microbial surfaces (Kaplan
and Volanakis, 1974; Szalai et al., 1995; Yuste et al., 2007;
Gang et al., 2015). CRP was shown to protect mice against
pneumococcal infection by binding to Phosphocholine (PCh),
but also by mechanisms independent on PCh (Gang et al.,
2015). Interestingly, CRP has been implicated in the regulation
of complement by binding to regulators, C4BP and factor H,
modulating the classical and alternative pathways, respectively
(Biro et al., 2007). A second role of CRP on complement
activation has been shown in pneumococci lacking PspC, where
the presence of CRP increased binding to FH (Jarva et al., 2002).
SAP has also been shown to increase complement deposition on
pneumococci by the classical pathway, leading to a more efficient
bacterial clearance; mice genetically deficient in SAP were more
susceptible to fatal pneumococcal infection, a condition that
was partially ameliorated by supplementation with human SAP
(Yuste et al., 2007).
The main result of complement activation by S. pneumoniae
is an increase in bacterial phagocytosis. Alveolar and monocyte-
derived macrophages play a central role in pneumococcal
clearance during subclinical pulmonary infections, mainly
through production of reactive nitrogen species (MacMicking
et al., 1997). Apoptosis has also been demonstrated to aid
pneumococcal clearance by macrophages which have exhausted
their capacity to kill ingested bacteria, in a nitric oxide (NO)
dependent manner [reviewed in (Aberdein et al., 2013)]. This
initial response is often enough to eliminate the invading
bacteria, with no clinical signs of disease. However, when
macrophages exceed their clearance capacity and can no longer
control bacterial spread, Th cells and neutrophils are recruited.
Production of Th1 and Th17 CD4+ cytokines contributes to
bacterial clearance, with activation of inflammatory responses.
Neutrophils are the main phagocytes controlling pneumococcal
loads at this stage; they produce proteases – including elastase
and cathepsin G – which mediate effective killing of ingested
bacteria [reviewed in (Aberdein et al., 2013)]. Phagocytosis
of pneumococci by this cell type is highly dependent on
complement activation. However, an exacerbated inflammatory
response leads to tissue damage and can be deleterious to the host.
Complement-mediated phagocytosis is also an important
mechanism of bacterial clearance during otitis media caused by
pneumococci, preventing bacterial spread; neutrophils from the
circulation reach the middle ear where they recognize and kill
bacteria coated with complement products (Sabharwal et al.,
2009). Also, a variation in bacterial resistance to phagocytosis
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in this niche has been associated with capsule production (Li
et al., 2012). Finally, the role of the complement system on
nasopharyngeal colonization by pneumococci is related to the
prevention of sepsis following mucosal colonization, and not to
the bacterial loads in the nasopharynx (Bogaert et al., 2010).
PNEUMOCOCCAL VIRULENCE
FACTORS INTERFERE WITH
COMPLEMENT ACTION
The ability to resist opsonization by C3 is considered crucial
not only during systemic infection, but also for persistence
of pneumococci in the host nasopharynx (Brown et al., 2002;
Kerr et al., 2005; Paterson and Mitchell, 2006; Paterson and
Orihuela, 2010) allowing further spread to other host niches.
In order to evade complement attack, the pneumococcus has
evolved multiple virulence factors that contribute to complement
resistance. A thick polysaccharide capsule acts in conjunction
with several surface proteins and toxins to limit complement
activation and/or accelerate complement products decay. The
importance of each of these molecules to complement evasion
will be discussed in the following sections. Table 1 and Figures 1B
and 2 summarize the role of the individual components on
complement.
Pneumococcal Polysaccharide Capsule:
The Major Virulence Factor
The vast majority of clinically important isolates of S. pneumoniae
are surrounded by a polysaccharide capsule with a highly
diverse composition; 97 different capsular types have been
identified to date (Geno et al., 2015). The capsule inhibits the
activation of both classical and alternative complement pathways,
protecting pneumococci against phagocytosis (Hyams et al.,
2010a). The bulky polysaccharide structure limits binding of
complement molecules, and also prevents the interaction of
surface-bound complement fragments with receptors on host
cells. Additionally, the capsule inhibits degradation of C3b
bound to the pneumococcal surface into iC3b (Hyams et al.,
2010a), resulting in a decreased iC3b/C3b ratio, which could
impact on complement-mediated bacterial interaction with CR3
on phagocytes. Therefore, protection afforded by the capsule
is able to reduce the opsonic capacity of the complement
system.
It has been demonstrated that the capsule inhibits binding
of IgG, IgM, and CRP to S. pneumoniae (Hyams et al.,
2010a). In the same work, Hyams et al. (2010a) used C1q-
deficient serum (unable to activate the classical pathway) to
show an increase in alternative pathway-mediated C3b/iC3b
deposition on non-encapsulated strains. Similar results were
found in other studies, which suggest a role for capsule in the
blockage of both classical and alternative complement pathways
(Abeyta et al., 2003; Hyams et al., 2010a, 2013). Noteworthy,
variations in the ability of different pneumococcal serotypes to
interfere with PspC-mediated FH binding showed a negative
correlation with their invasiveness (Hyams et al., 2013). In
that work, the levels of FH binding directly impacted on the
C3b/iC3b deposition and neutrophil association, suggesting
that pneumococcal capsule types may influence phagocytosis
through their effects on FH binding. The polysaccharide capsule
also plays a role in preventing the immune adherence of
pneumococci – a complement-dependent process in which
the bacteria bind to erythrocytes, are transported and
transferred to macrophages, which results in reduction of
the phagocytic activity against encapsulated pneumococci
(Li et al., 2009).
TABLE 1 | Pneumococcal virulence factors: anticomplement activities.
Factors Target molecule Effects
Capsule IgM, IgG, CRP, C3, and iC3b Prevents complement activation. Inhibits bacterial opsonization by C3b and iC3b.
PspAa CRP and FB Inhibits CRP deposition and C3 convertase formation
PspC FH, C4BP, Vitronectin, C3 Inhibits C3 convertase formation and MAC assembly.
Ply C1q, IgG, and L-Ficolin Activates complement away from bacterial cells and depletes complement components.
Phtsa∗ FH and C3 Inhibits C3 convertase formation.
NanA/BgaA/StrH − Deglycosylate complement components.
LytAb FH, C4BP, C3b, and iC3b Inhibits C3 convertase formation and reduces opsonization by iC3b.
LytBa − Lytic activity promotes bacterial dispersion which limits complement deposition
PepOc C1q, C4BP, PLG Activates and depletes complement. Inhibits C3 convertase formation.
GAPDHacd C1q, PLG Activates and depletes complement.
Enocd C4BP, PLG Inhibits C3 convertase formation and depletes complement.
PGKe C5, C7, C9, and PLG Inhibits MAC formation and depletes complement.
Tufspe FH, FHL-1, CFHR-1, and PLG Inhibits C3 convertase formation and depletes complement.
RrgA CR3 Promote adhesion to and invasion of macrophages.
aPossible mechanism; not completely elucidated.
b Indirect activity. Inhibits binding between C1q and CRP.
cExplores PLG in order to improve adhesion and colonization.
dPossibly cleaves/depletes complement components by binding to PLG, but this was not investigated.
eBinding to PLG possibly improves adherence and invasion, but this was not investigated.
∗Two studies found conflicting results for Pht binding to FH.
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FIGURE 2 | Role of pneumococcal virulence factors in evasion from the Complement System. The polysaccharide capsule prevents binding of IgG, IgM,
and CRP to the bacterial surface, as well as C3b and iC3b, thereby impairing complement activation by classical (CP) and alternative pathways (AP). The proteins
have been grouped according to their interactions with complement. T indicates direct inhibition by pneumococcal antigens. PspA affects C3 convertase formation
by interfering with FB and prevents CRP binding to phophocholine on the bacterial wall, thus inhibiting activation of the classical pathway. PspC binds to FH and
C4BP promoting the inhibition of C3 convertase formation and accelerating C3 convertase decay. PspC also cleaves C3 molecules generating products that cannot
activate complement. Binding of PspC to Vitronectin reduces MAC formation. Phts bind to FH and cleave C3. LytA binding to FH and C4BP reduces C3 convertase
formation and promotes its dissociation. It also inhibits the interaction between CRP and C1q. In addition, LytA is able to split up C3b and iC3b. PLY released from
the bacterium activates the classical pathway through interactions with IgG, C1q, and L-ficolin, and depletes complement. The exoglycosidases NanA, BgaA, and
StrH remove sialic acid (SA) from complement components; also, SA favors FH activity in regulation of C3 convertase. PepO binds to C1q and activates
complement when released from the pneumococcal surface, leading to depletion of complement components. PepO binding to C4BP results in down regulation of
classical pathway activation. Eno decreases C3 convertase formation by binding to C4BP. GAPDH on its free form or attached to the bacterial surface binds to C1q,
likely promoting complement activation. PGK impairs MAC assembly by binding to C5, C7, and C9. Tuf binds to FH and FHL-1 inhibiting formation and accelerating
dissociation of C3 convertase. Tuf can also bind to CFHR-1, but the implications of this interaction are not completely elucidated. The main result of such
interactions is an impaired bacterial phagocytosis. Also, pneumococcal proteins use complement molecules as bridges to interact with host receptors and favor
bacterial adherence and invasion. PspC exploits FH to adhere and invade host cells. PepO uses C1q to increase bacterial adherence. RrgA improves colonization by
binding to complement receptor 3 (CR3). Finally, the ability to interact with PLG – as demonstrated for PepO, Eno, and GAPDH with PLG was shown to degrade the
host extracellular matrix components (ECM) and to improve invasion, while PepO, PGK and Tuf bound to PLG inactivate C3 and C3b.
Interestingly, the extension of complement resistance
provided by the capsule varies depending on the bacterial
serotype. Mutant strains with a TIGR4 background and capsular
types 4 or 7F were more resistant to complement deposition and
phagocytosis than those expressing polysaccharides 6A or 23F
(Hyams et al., 2010b). Furthermore, this increased resistance to
complement deposition correlated with an increased virulence
for those strains in a mouse model of pneumococcal sepsis.
Accordingly, a study investigating a serotype 11A pneumococcal
strain found a correlation between the low invasiveness of
this isolate and the presence of O-acetylated epitopes in the
polysaccharide structure, which were recognized by ficolin-2 and
activated the lectin pathway, leading to bacterial phagocytosis
(Brady et al., 2014).
On a whole, the evidence suggests that capsular
polysaccharides play a central role in pneumococcal escape
from complement system through multiple mechanisms,
impacting the bacterial ability to cause disease.
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Pneumococcal Proteins as Sentinels
against the Complement System
Besides the capsule, pneumococci express many proteins that
interact with the complement system and promote an increased
survival against this important host defense mechanism. These
molecules contribute to virulence, as they are essential to the
progression of disease and usually found on the bacterial surface,
cytosol, in the cell wall or even being released to the environment.
Among the anti-complement proteins are PspA, PspC, Phts,
LytA, LytB, LytC, NanA, SrtH, BrgA, PLY, PGK, Eno, GAPDH,
PepO, and Tuf, which will be discussed individually in the
following sections.
Pneumococcal Surface Protein A (PspA)
Pneumococcal surface protein A is present in virtually all
pneumococcal isolates, independently of the serotype. It attaches
to phosphocholine residues on the cell wall through the
C-terminus, while the N-terminal domain is exposed on the
bacterial surface (Yother and Briles, 1992); this region presents
a pattern of sequence variation that was used to classify PspA
proteins into six clades, included in three families (Hollingshead
et al., 2000). All families are involved with inhibition of
complement activation (Tu et al., 1999; Ren et al., 2003,
2004b) in the early phases of infection (Ren et al., 2004b),
although the molecular mechanism of PspA interaction with
complement has not been completely elucidated. A recent study
demonstrated that PspA competitively inhibits binding of CRP to
the phosphocholine moieties on the bacterial wall, thus limiting
complement deposition through the classical pathway (Mukerji
et al., 2012).
The inhibition of C3 deposition by PspA was attested by the
observation that pneumococci lacking PspA were less virulent
and more susceptible to C3 deposition than the wild-type
strain, while the virulence of the PspA− strain was recovered
in complement factor B-deficient knockout mice (Tu et al.,
1999). This evidence suggests that the inhibitory role of PspA
over complement is related to FB activation, indicating an
important contribution for the alternative complement pathway.
In contrast, an in vitro study from (Ren et al., 2004b)
found that C3b deposition on mutant pneumococci lacking
PspA was dependent on the classical pathway activation, since
blockage of the classical pathway (with EGTA) – but not the
alternative pathway (using sera from FB deficient mice) –
completely abrogated C3 deposition in the absence of PspA.
However, when both complement pathways were present, C3
deposition on the PspA− strain was much greater than with
either pathway alone (Ren et al., 2004b). The authors conclude
that while the classical pathway is required for activation of
complement on PspA− pneumococci, the alternative pathway is
responsible for the amplification of C3 deposition (Ren et al.,
2004b).
A study investigating the effects of PspA on complement
mediated defense against pneumococci in vivo demonstrated
a role for complement receptors CR1/2, since bacteria lacking
PspA become virulent in knockout mice for this receptor. Also,
mice that did not express factor D were more susceptible to
infection with the PspA− strain, confirming the importance of the
alternative pathway for PspA mediated complement inhibition
(Ren et al., 2004a). Furthermore, analysis of the fragments
derived from C3 degradation on the pneumococcal surface (C3b
and iC3b) showed increased levels of iC3b on the mutant strain,
suggesting that PspA prevents processing of C3b into iC3b
(Ren et al., 2004a). Finally, it has been shown that PspA-induced
inhibition on complement deposition reduces bacterial clearance
by phagocytes in vitro (Ren et al., 2012).
An additional effect of PspA’s inhibition of complement
deposition is the ability to reduce the immune adherence of
the bacterium to erythrocytes (as described for the capsular
polysaccharides), thus limiting pneumococcal clearance through
phagocytosis (Li et al., 2007). This effect was further enhanced
in mutant strains lacking PspA and PspC (another complement-
interacting protein that will be discussed in the following section),
suggesting that these proteins can act synergistically, promoting
a strong complement inhibition (Li et al., 2007).
The anti-complement properties of PspA can be abrogated by
host immune response against this protein (Ren et al., 2012).
A strong correlation between increased survival and the levels
of complement deposited onto pneumococci coated with anti-
PspA antibodies, has been reported in mice immunized with
PspA fragments, suggesting that the blockage of PspA contributes
to pneumococcal clearance mediated by complement (Darrieux
et al., 2007; Moreno et al., 2010; Goulart et al., 2011). A similar
result was obtained using sera from humans immunized with
PspA (Ochs et al., 2008). Furthermore, antibodies against PspA
purified from mice which had been immunized with heat-killed
pneumococci promoted an increase in complement deposition
on the bacterial surface (Khan et al., 2015).
Once the bacteria are coated with anti-PspA antibodies
and complement, they can be recognized more efficiently by
phagocytes and eliminated. Goulart et al. (2011) demonstrated
that antibodies induced by mouse immunization with the
N-terminal region of PspA from different clades were able
to increase phagocytosis of diverse pneumococcal strains by
mouse peritoneal phagocytes in presence of a complement
source. This effect was confirmed in later studies using different
opsonophagocytosis assay (OPA) protocols (Ren et al., 2012;
Genschmer et al., 2013) and reinforces the ability of anti-
PspA antibodies to promote bacterial phagocytosis through
complement’ activation.
Pneumococcal Surface Protein C (PspC)
Pneumococcal surface protein C is a multifunctional protein,
able to interact with complement components C3 (Cheng et al.,
2000), human factor H (FH) (Janulczyk et al., 2000; Dave et al.,
2001) and the regulator C4BP (Dieudonne-Vatran et al., 2009),
and also functions as an adhesion protein, recognizing secretory
immunoglobulin A (SIgA) through the secretory component
(SC) (Dave et al., 2004; Kerr et al., 2006). PspC also interacts
with a laminin-integrin receptor, improving bacterial adherence
and spread to other sites (Orihuela et al., 2009). Moreover,
PspC displayed affinity to other components of the extracellular
matrix, such as thrombospondin-1 and vitronectin, further
enhancing bacterial dissemination (Voss et al., 2013; Binsker
et al., 2015).
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Pneumococcal surface protein C contains an N-terminal
α-helical domain which is exposed at the surface of the bacterium,
followed by a proline-rich region and a cell surface-anchoring
region (Brooks-Walter et al., 1999). PspCs are classified into 11
groups according to its genetic variation (Iannelli et al., 2002).
Different studies demonstrated that PspC from multiple clinical
isolates of pneumococci exhibit strong binding to FH (Lu et al.,
2006; Moreno et al., 2012).
Pneumococcal surface protein C is able to interact directly
with C3 through non-covalent binding to the α and β chains
of the C3 molecule, preferentially to the alpha fragment (Cheng
et al., 2000). Moreover, it has been shown that PspC interacts
with C3 produced by lung epithelial cells, and that this interaction
potentiates bacterial adherence (Smith and Hostetter, 2000). The
impact of this interaction in pneumococcal disease was confirmed
by Kerr et al. (2006) working with infected C3−/− mice; they
found that pneumococci lacking PspC presented poor virulence
in WT mice, while their potential to cause disease was fully
restored in C3 deficient knockout mice.
Pneumococcal surface protein C bound to vitronectin
inhibited MAC formation (Jarva et al., 2002; Zipfel et al., 2008;
Voss et al., 2013; Kohler et al., 2015), thus acting as a complement
regulator, while improving the uptake of pneumococci by host
cells (Bergmann et al., 2009). Despite the reduced susceptibility
of pneumococci to MAC-mediated lysis, the combined effects of
PspC interaction with vitronectin over the complement system
contribute to pneumococcal virulence.
Pneumococcal surface protein C is able to recruit FH
to the pneumococcal surface with a consequent reduction
in complement activation, as demonstrated by an in vitro
opsonophagocytosis assay (Jarva et al., 2002). PspC-FH
interaction has also been shown to occur in vivo (Quin et al.,
2005). The interaction between PspC and FH inhibits C3bBb
formation by competition with factor B (FB) (a Bb precursor) for
binding to C3b; it also accelerates irreversible C3bBb decline by
relocating Bb, and acts as a cofactor for factor I (FI)-catalyzed
C3b cleavage, yielding iC3b that cannot bind FB (Herbert et al.,
2015). More recently, the implications of FH-PspC binding were
investigated in vivo, during experimental human colonization
with S. pneumoniae (Glennie et al., 2016). The authors found
that individuals with epithelial inflammation and increased FH
levels (due to influenza virus infection) had increased bacterial
loads after experimental colonization, when compared to healthy
subjects. Interestingly, the presence of antibodies against PspC
did not affect in vivo binding of PspC with factor H, possibly
because interaction with factor H limits the recognition of PspC
by specific antibodies (Glennie et al., 2016). Furthermore, FH
is exploited by PspC as a bridge to interact with host cells.
Simultaneous binding of FH to PspC on the bacterial surface and
the CR3 integrin on polymorphonuclear leukocytes (PMN) and
CR3 expressing epithelial cells promoted bacterial adhesion and
uptake (Agarwal et al., 2010). While the interaction with PMN
may favor bacterial clearance, the increased adherence promoted
by PspC interaction with FH is a necessary step for successful
colonization (Quin et al., 2007; Agarwal et al., 2010). In fact, the
adherence mediated by FH was related to an increased virulence
during lung infection in mice (Quin et al., 2007).
In the biofilm phenotype of pneumococci, the expression
of PspC was increased as well as the recruitment of FH.
Also, the alternative complement pathway activation was
impaired, providing a less propitious condition for phagocytosis
(Domenech et al., 2013).
The ability of PspC to avoid complement attack was confirmed
by Herbert et al. (2015), who found that FH bound to PspC
displays a conformational change which causes an enhanced
exposure of C3 binding sites (Herbert et al., 2015). As a result,
the interaction of PspC-bound FH with C3b was increased
twofold, while the alternative pathway convertase disassociation
was increased fivefold (Herbert et al., 2015). In summary,
PspC’s ability to interact with the complement system is the
most important contribution of this molecule to pneumococcal
pathogenicity, and provides an interesting target for protein-
based vaccines.
Pneumococcal Histidine Triad (Pht)
Pneumococcal histidine triad (Phts) is a family of proteins
exposed on the surface of S. pneumoniae. This group is composed
by four members, PhtA, PhtB, PhtD, and PhtE, which are
characterized by the presence of histidine triads (HxxHxH)
repeated 5 or 6 times in their amino acid sequences (Adamou
et al., 2001). Due to the large number of histidine residues
in the triads, it has been suggested that Phts may bind to
nucleoside or metals. In fact, Phts demonstrate high affinity for
divalent cations, with 5 to 6 zinc binding domains (Adamou
et al., 2001; Rioux et al., 2011). Zinc is involved in the positive
regulation of Phts. Furthermore, variations in zinc concentration
on different host niches correlate with the level of Phts expression;
Phts are upregulated in the nasopharynx and lungs – where
zinc availability is higher – with a reduced expression in blood
(Ogunniyi et al., 2009). Despite the variations in Pht levels
in different host niches, immunization with Pht fragments
is protective in models of bacterial colonization and sepsis
(Godfroid et al., 2011).
It has been suggested that Phts interact with complement
factor H. However, studies evaluating the binding of Phts to
FH in vitro revealed conflicting results. Ogunniyi et al. (2009),
using FH-enzyme-linked immunosorbent assay and western
blot, showed that all Phts bind to factor H, although this
interaction was much lower when compared to PspC (positive
control). More recently, Melin et al. (2010) used FH-ELISA
and demonstrated that Pht proteins did not bind to factor
H in most of the serotypes tested; they concluded that the
capsule type influences Phts’ ability to interact with FH. In
the same work, Melin et al. (2010) used western blot analysis
to show that FH was able to bind to cell lysates of Pht−
pneumococcal strains, an effect that was dependent on the
presence of PspC. The contribution of PspC for FH binding
was attested by the abolished binding of this complement
regulator, to mutants lacking PspC; in another experiment using
flow cytometry, they showed that among five Pht− mutants of
different serotypes, only the type 4 strain was able to interact
with factor H. They concluded that the relative contribution of
Pht proteins to complement inhibition is likely to be affected
by the presence of other pneumococcal proteins and, most
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importantly, depends on the genetic background (Melin et al.,
2010).
In summary, the putative role of Phts in the binding to
FH remains unclear, although their influence in complement-
mediated phagocytosis was in fact observed. Studies with mutant
strains negative for all Phts show an increased susceptibility to
bacterial opsonization by C3. It was also suggested that a PhtA
fragment could cleave human C3 (Hostetter, 1999). Therefore,
further studies are needed in order to elucidate the role of Phts
in complement-mediated immunity, which should contribute to
the evaluation of their potential as pneumococcal vaccines.
Murein Hydrolases
Murein hydrolases are enzymes that degrade and remodel the
cell wall, and are classified based on the substrate they target.
This family of proteins includes amidases, glucosaminidases,
muramidases (also termed as lysozymes), endopeptidases and
transglycosylases. S. pneumoniae exhibits three main murein
hydrolases: LytA, LytB, and LytC.
LytA, B, and C are choline binding proteins attached to the
pneumococcal surface, involved in pneumococcal cell division –
particularly LytB (Garcia et al., 1999) and cell wall remodeling
(Gosink et al., 2000; Bai et al., 2014). They have also been
shown to improve the adhesion/colonization of human and
rat nasopharyngeal cells (Gosink et al., 2000; Bai et al., 2014).
The loss of LytB and LytC expression results in an increased
susceptibility to phagocytosis by alveolar macrophages and
neutrophils (Ramos-Sevillano et al., 2011).
LytA interacts with the complement system in many ways.
It binds to C4BP and FH, preventing complement deposition
by classical and alternative pathways (Ramos-Sevillano et al.,
2015). It has also been demonstrated that LytA inhibits binding
of C1q to CRP, which was related with an increased exposure
of Phosphocholine molecules in the LytA-negative mutant
strain (Ramos-Sevillano et al., 2015). LytA can cleave C3b and
iC3b fragments deposited in the bacterial surface regardless
of the presence of capsule (Ramos-Sevillano et al., 2015),
reducing opsonic activity and subsequent phagocytosis. Indeed,
phagocytosis by neutrophils and alveolar macrophage cells was
described to be higher in the lytA mutant strain (Ramos-Sevillano
et al., 2012). The mutant strain also displayed an increased
complement deposition when compared with the parental strain
expressing autolysin (Ramos-Sevillano et al., 2012).
LytC negative pneumococci show an increased C3b deposition
on their surface, an effect that was not observed with the
LytB mutant (Ramos-Sevillano et al., 2011). However, despite
the absence of a direct effect of LytB alone on complement
deposition, a double mutant lacking LytB and LytC revealed a
higher sensitivity to C3b deposition when compared with the
single LytC mutant (Ramos-Sevillano et al., 2011). This suggests a
contribution of both proteins to control complement deposition
on pneumococci, an effect that was related to increased virulence
in models of colonization and invasive disease in presence of LytB
and LytC (Ramos-Sevillano et al., 2011).
Despite the evidence of LytA, LytB and LytC involvement in
complement resistance by S. pneumoniae, the exact mechanism
by which they confer resistance to complement is not completely
clear. It is possible that the chain-dispersing function of these
hydrolases influences the amount of C3 deposition on the
bacterial surface. Growing of S. pneumoniae in biofilms was
shown to reduce complement deposition and confer resistance to
its opsonic activity and subsequent phagocytosis, when compared
to bacteria in diplococci morphology. Indeed, the absence
of LytA and LytB was found to promote formation of long
chains of pneumococci, while the WT strain yielded diplococci
morphology (Domenech et al., 2013). In addition, treatment of
long pneumococcal chains with LytB led to bacterial dispersion
into diplococci or short chains (De Las Rivas et al., 2002; Dalia
and Weiser, 2011; Domenech et al., 2013). This result suggests
a link between colony morphology and complement deposition
on pneumococci, while indicating a role for autolysins in this
mechanism.
Pneumolysin (PLY)
Pneumolysin (PLY) is a cytotoxic protein produced by all
strains of S. pneumoniae, found in the cytosol and cell
wall compartments (Price and Camilli, 2009), and also being
released from the bacterium during cell growth (Balachandran
et al., 2001). PLY displays many important functions during
pneumococcal infections, including (i) hemolytic and genotoxic
effects (Johnson et al., 1980; Rai et al., 2016); (ii) induction of
apoptosis in different cells – including macrophages and brain
cells (Braun et al., 2001; Srivastava et al., 2005); (iii) interaction
with TLR-4 and production of inflamatory cytokynes (Malley
et al., 2003); (iv) activation of NLRP3 inflamasome (McNeela
et al., 2010); (v) induction of neutrophil extracelullar trap (NET)
formation (Nel et al., 2016); (vi) inhibition of cilliary movements
in epithelial respiratory cells (Rayner et al., 1995; Marriott
et al., 2008) and (vii) complement activation (Paton et al., 1984;
Mitchell et al., 1991; Benton et al., 1997; Alcantara et al., 2001;
Jounblat et al., 2003; Yuste et al., 2005; Propst-Graham et al.,
2007; Marriott et al., 2008; Ali et al., 2013).
Pneumolysin’s ability to activate complement – which could
be interpreted as disadvantageous for pneumococci – has actually
been reported as a protective mechanism for the pathogen; since
PLY is only exposed to interact with complement when it is
released from the bacterium (the cell wall-attached molecule is
not accessible to recognition by antibodies or complement), it
has been suggested that complement activation by PLY causes
depletion of complement components in the serum (Paton et al.,
1984; Mitchell et al., 1991), thus limiting complement binding
to the pneumococcus. This effect was confirmed in vivo using
mutant strains that produce truncated forms of the toxin (Rubins
et al., 1995; Alcantara et al., 2001; Propst-Graham et al., 2007); in
a lung infection model, a mutant strain expressing a PLY which
lacks the complement activation activity displayed a marked
reduction in bacterial loads in the mice lungs (Rubins et al., 1995;
Propst-Graham et al., 2007). Similarly, complementation of a
PLY negative mutant with a recombinant PLY presenting intact
complement activation capacity but no hemolytic activity was
able to restore the bacterial virulence, indicating an independent
contribution of the complement activation motif of PLY for
pneumococcal virulence in this infection model (Rubins et al.,
1995). However, in models of pneumococcal bacteremia, a
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significant role for the complement activity of PLY was only
observed in cirrhotic rats (which produce reduced amounts
of complement), with no effect in animals exhibiting normal
complement production (Alcantara et al., 1999). This result
suggests that the contribution of the complement activation motif
of PLY is important in host niches or systems where a limited
amount of complement is available (Propst-Graham et al., 2007;
Marriott et al., 2008).
Pneumolysin’s ability to activate complement occurs mainly
through the classical pathway; in fact, a direct interaction of PLY
with C1 has been described in vitro (Paton et al., 1984) and related
to a specific region of PLY that shows homology to human CRP,
located in the domain 4 (Mitchell et al., 1991). PLY also shows
structural similarity with the Fc portion of immunoglobulin,
being able to bind Ig (Mitchell et al., 1991). Interestingly, the
region involved in interaction with Ig is the same responsible for
PLY self-oligomerization, suggesting one mechanism by which
PLY promotes the complement activation [reviwed in (Marriott
et al., 2008)]. However, complement activation by PLY is not
dependent on the presence of specific anti-PLY antibodies,
since sera from unvaccinated humans and non-immune mice
showed increased C3 deposition on pneumococci lacking PLY
(Yuste et al., 2005). Additionally, the contribution of PLY to
complement-mediated inflammatory response may be enhanced
by the fragments generated from complement activation (C3a
and C5a), which attract polymorphonuclear cells, as already seen
in serum containing high amounts of PLY (Johnson et al., 1981).
The observation that human serum (but not mice) depleted
from C1q still promotes PLY opsonization by C3 activation
products suggests a role for the lectin pathway in PLY-induced
complement activation (Ali et al., 2013). In fact, human L-ficolin
has been shown to initiate MBL activation by PLY in human
serum, contributing to the classical pathway activation (Ali et al.,
2013).
In addition to its direct role in complement activation, PLY
participates in the assembly of pneumococcal biofilms (Shak
et al., 2013) – a phenotype that is important for successful
colonization and during the early stages of invasive infections,
as well as limiting the interaction of complement components
with surface molecules of pneumococci (Hall-Stoodley et al.,
2006; Domenech et al., 2013). Therefore, the involvement of
PLY on biofilm formation indirectly contributes to evasion from
complement.
In summary, the contribution of PLY to pneumococcal
virulence – which is highly influenced by the ability to interact
with the complement system – reinforces the importance of
complement evasion for bacterial survival, as well as PLY’s
potential as a vaccine candidate against this pathogen.
Pneumococcal Exoglycosidases
The pneumococcal exoglycosidases are a group of enzymes
that cleave terminal sialic acid from glycoconjugates. Among
five exoglycosidases expressed by pneumococci – NanA, NanB,
NanC, BgaA, and StrH, three surface associated molecules have
been shown to interact with complement: NanA, BgaA, and StrH.
Neuraminidase A (NanA) is able to remove the sialic acid
(SA) from a range of host substrates, thereby promoting the
interaction between pneumococci and host cell receptors
that contribute to pneumococcal colonization (Tong et al.,
2000; Brittan et al., 2012). BgaA is the only pneumococcal
β-galactosidase; it is secreted and acquired by the pneumococcal
surface through a sortase. BgaA exhibits affinity to terminal
galactose β (1–4) linked to GlcNAc, suggesting a role in
deglycosylation of glycoconjugates of human cells (?) and was
shown to be an adhesin, regardless of its galactosidase activity
(Limoli et al., 2011). N-acetylglucosaminidase (StrH) is an
exoglycosidase found in the bacterial surface and supernatant,
able to cleave N-acetylglucosamine (GlcNAc) that is linked
to mannose through β-1 (Zähner and Hakenbeck, 2000). All
three proteins have been reported to work sequentially in
the deglycosylation of SA, galactose, N-acetylglucosamine,
decrypting mannose of host glycoproteins, which favors
adherence/colonization (King et al., 2006).
These proteins have also been shown to deglycosylate human
glycoconjugates as lactoferrin and IgA (King et al., 2006),
demonstrating a direct interaction with the immune system.
Indeed, SA participates in several immune processes such
as leukocyte rolling, cell activation, modulation of immune
cell functions and interactions with the complement system
[reviewed in (Varki and Gagneux, 2012)].
NanA, BgaA, and StrH were shown to act in conjunction
to limit complement deposition on pneumococci of different
genetic backgrounds (Dalia et al., 2010). Blocking of the
classical pathway did not affect complement levels on the
bacterial surface, suggesting that NanA acts on the alternative
pathway (Dalia et al., 2010). These proteins were also shown
to inhibit bacterial killing by human phagocytes in vitro.
This effect was attributed to the sequential removal of sugar
moieties from host glycoconjugates by NanA, BgaA, and StrH:
NanA removes sialic acid that is α2–3 or α2–6 linked to
galactose, BgaA excises the galactose that is β1–4 linked to
N-acetylglucosamine, and StrH removes N-acetylglucosamine
that is β1 linked to mannose (King et al., 2006). Since
complement components contain many glycosylation sites which
are necessary for their functions [reviewed in (Ritchie et al.,
2002)], the sequential activities of NanA, BgaA, and StrH
possibly deglycosylate one or more glycoproteins that are
important for complement deposition, thus leading to inhibition
of complement mediated opsonophagocytosis (Dalia et al.,
2010).
Previous studies found a role for SA in subversion of
complement alternative pathway. SA is required for effective
binding between FH and surface-attached C3b, as well as
for dissociation of C3 convertase in sheep erythrocytes
(Fearon, 1978). Pathogens like Neisseria meningitidis and
Haemophilus influenzae exploit this complement-evasion
strategy by producing SA that binds factor H (Ram et al., 1998).
Interestingly, NanA from S. pneumoniae is able to remove sialic
acid from the surface of these pathogens, thus limiting their
ability to escape complement attack, providing a competitive
advantage for pneumococci (Shakhnovich et al., 2002).
In summary, despite the evidence of exoglycosidases role
in complement evasion, further investigations are required in
Frontiers in Microbiology | www.frontiersin.org 10 February 2017 | Volume 8 | Article 224
fmicb-08-00224 February 16, 2017 Time: 16:38 # 11
Andre et al. Complement Evasion by Pneumococcal Virulence Factors
order to elucidate the exact mechanism by which these proteins
circumvent complement activation.
Pneumococcal Pilus Adhesine (RrgA)
Streptococcus pneumoniae expresses a pilus-like structure,
encoded by the rlrA pilus islet 1, which contributes to
virulence in animal models of pneumococcal infection (Barocchi
et al., 2006). This structure is composed of three proteins:
RrgA, RrgB, and RrgC (Barocchi et al., 2006; Hilleringmann
et al., 2009). RrgA is an adhesin that interacts with lung
epithelial cells in vitro and confers virulence in mice (Barocchi
et al., 2006; Hilleringmann et al., 2009). It is also able to
increase bacterial phagocytosis by murine and human cells
(Hilleringmann et al., 2009). Orrskog et al. (2012), using flow
cytometry have shown that purified complement receptor 3
(CR3) binds to pneumococci expressing RrgA, and that purified
RrgA is able to interact with the CD11b integrin domain of CR3.
In addition, RrgA expression was linked to a faster dissemination
of pneumococci from the upper respiratory tract and peritoneal
cavity to the bloodstream of challenged mice, and to an
increased bacterial survival inside macrophages (Orrskog et al.,
2012). Altogether, the evidence indicate that RrgA interaction
with CR3 on the surface of macrophages promotes bacterial
internalization, while a prolonged survival of the internalized
pneumococci contributes to their dissemination during systemic
infection.
Pneumococcal Moonlighting Proteins
Moonlighting proteins are a group of molecules able to
perform distinct biological activities through a single domain.
Found in both prokaryotic and eukaryotic cells, these proteins
display several activities, including roles in metabolic processes,
host-pathogen signaling, transcription activation, adhesion and
invasion of host tissues (Henderson and Martin, 2014).
Based on their potential to interact with host cells, bacterial
moonlighting proteins are important virulence factors in
prokaryotic organisms (Jeffery, 1999; Henderson and Martin,
2011).
One important feature shared by many moonlighting proteins
is their ability to interact with plasminogen (PLG) (Henderson
and Martin, 2011), a plasmatic glycoprotein that generates
plasmin (PL) upon activation. PL is a serine protease which
displays many functions in tissue remodeling and coagulation.
The conversion of PLG into PL is accomplished by activators
like urokinase type A (uPA) and tissue type plasminogen (tPA)
activators (human molecules) or by bacterial proteins [reviewed
in (Lahteenmaki et al., 2001)].
Plasminogen and PL interfere with many molecules of the
complement system (Barthel et al., 2012; Castiblanco-Valencia
et al., 2016). PL cleaves C1, C2, C3, C3b, C4, and C5 (Pillemer
et al., 1953; Amara et al., 2010; Barthel et al., 2012), thereby
depleting and inhibiting complement activation through all three
complement pathways. Even the enzymatically inactive PLG was
able to improve the cofactor activity of FH in the inactivation
of C3b by Factor I (Foley et al., 2015). It also cleaves iC3b,
yielding C3dg-like, which acts as an opsonin and an activator of
proinflammatory cytokines in macrophages (Foley et al., 2015).
PLG has been found to interact with C3, C5, C3b, C3c, and C3d
(Barthel et al., 2012).
Streptococcus pneumoniae expresses moonlighting proteins
(Henderson and Martin, 2013), including PepO, enolase,
GAPDH, PGK, and Tuf, which are able to acquire surrounding
PLG molecules of the host. This interaction has been shown to
contribute to invasion of host tissues and to avoid complement
attack. The actions of pneumococcal moonlighting proteins are
described in more detail below.
Endopeptidase O (PepO)
Endopeptidase O (PepO) displays a HEXXH motif, an important
active site of neutral endopeptidase (NEP) and typical of
zinc-dependent metallopeptidases (Rawlings and Barrett, 1995).
NEP is a member of M13 peptidase family, involved in
many physiological functions and immune responses. Found
on the pneumococcal surface and in culture supernatants,
endopeptidase O has been reported to bind plasminogen and
fibronectin (constituent of human extracellular matrix) (Agarwal
et al., 2013b), thereby coating the pneumococcal surface with
these molecules, which facilitate pneumococcal adhesion and
invasion of host cells, while inhibiting complement-mediated
immunity. Indeed, the binding of PepO to PLG in the presence
of uPA was able to cleave C3b (Agarwal et al., 2013b).
In addition, PepO has been found to bind to both C1q
(C-terminal globular heads) and C4BP (CCP8 of the α-chain)
through ionic interactions (Agarwal et al., 2014), with direct
implications on complement activation. The ability to bind
C1q upon release of PepO promotes complement activation
and rapid consumption of complement components around
the bacterium, with a consequent inhibition of complement
activation on the pneumococcal surface (Agarwal et al., 2014).
Further inhibition of complement activation is achieved by
interaction with the complement regulator C4BP (Agarwal
et al., 2014). Also, the interaction of surface exposed PepO
with C1q increases pneumococcal adherence to host epithelial
cells in vitro (Agarwal et al., 2013a, 2014; Agarwal and Blom,
2015).
α-Enolase (Eno)
Pneumococcal α-Enolase (Eno) is present in virtually all strains,
found in the bacterial cytoplasm, displayed on the surface and
released to the culture supernatant. The mechanism of Eno
exportation is not completely elucidated, although it does not
seem to be dependent on autolysis (Bergmann et al., 2003). It
is a glycolytic enzyme involved in conversion of 2-phospho-
D-glycerate to phosphoenolpyruvate during glycolysis (Whiting
et al., 2002). Similar to other moonlighting proteins, it has
been shown to play a role in bacterial adherence to host tissues
and invasion by binding to PLG and, consequently, promoting
degradation of extracellular matrix components (Bergmann
et al., 2005; Bergmann et al., 2013). Eno-deficient pneumococcal
mutants displayed reduced binding to PLG, which correlated
with a reduced adherence to host cells in vitro (Bergmann et al.,
2013).
Pneumococcal Eno exhibits additional roles in virulence.
It was reported to ionically bind to C4BP (Agarwal et al.,
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2012), consequently coating the surface of pneumococci with
this complement regulatory molecule. The binding sites were
identified in the CCP domains of α-chain in C4BP. It was also
reported that Eno can concomitantly bind to C4BP and PLG
in a non-competitive fashion, increasing the activation of PLG
into plasmin (Agarwal et al., 2015). Furthermore, C4BP bound
to Eno on the pneumococcal surface acted as a cofactor in C4d
degradation by FI, while leading to a reduction in C3b deposition
on the bacterium (Agarwal et al., 2012). Additionally, Eno has
been shown to interact with neutrophils promoting formation
of neutrophil extracellular traps (NETs) which increased their
bactericidal effect (Mori et al., 2012). One possible explanation
for this apparently disadvantageous interaction is that NET-
induced host tissue damage may favor the spread of the
microorganism; however, this effect has not been investigated to
date.
Glyceraldehyde-3-phosphate Dehydrogenase (GAPDH)
Glyceraldehyde-3-phosphate Dehydrogenase is a glycolytic
enzyme shared by prokaryotic and eukaryotic cells which has
been implicated in the pathogenesis of bacterial infections
(Jin et al., 2011), acting as an adhesion (Pancholi and Fischetti,
1992; Zhang et al., 2015), a transferrin binding molecule (in
both bacteria and human cells) (Modun and Williams, 1999;
Raje et al., 2007; Kumar et al., 2012) as well as in host immune
modulation and apoptosis (Terao et al., 2006; Terrasse et al.,
2012).
Although first identified as a cytoplasmic protein, it has been
demonstrated that pneumococcal GAPDH is surface-associated
and surface-exposed (Terrasse et al., 2012, 2015), where it can
act as an adhesin and bind PLG (Attali et al., 2008). Binding of
PLG to pneumococci increased bacterial adherence and invasion
of host cells (Attali et al., 2008). GAPDH released through
autolysis is also able to bind C1q (Terrasse et al., 2012) and
to activate complement. Pneumococci lacking the glycolytic
enzyme exhibited reduced binding to PLG and deposition of
C1q, C3 and C4 components (Terrasse et al., 2012), evidencing
a role of GAPDH in the activation and subsequent deposition of
complement.
Glyceraldehyde-3-phosphate Dehydrogenase was reported to
bind directly to peptidoglycan regardless of the presence of
teichoic or lipoteichoic acids, though a mechanism dependent
on LytA-mediated lysis (Terrasse et al., 2015). In the same
study, peptidoglycan bound GAPDH showed an increased
C1q deposition (Terrasse et al., 2015); however, C1q binding
in the presence of GAPDH was not able to activate the
complement cascade, suggesting that other molecules may be
involved in complement activation in this model (Terrasse et al.,
2015).
The implications of binding of GAPDH (free form) to
C1q may be similar to those found for PepO, leading
to depletion of complement components away from the
bacterium, and consequently avoiding complement mediated
pneumococcal clearance. However, the precise mechanism
of GAPDH – attached to the pneumococcal surface or
not – interaction with the complement system has not been
investigated.
Phosphoglycerate Kinase (PGK)
Phosphoglycerate Kinase is a glycolytic enzyme involved in
the conversion of 1,3-biphosphoglycerate to 3-phosphoglycerate
(Bernstein et al., 1998). As reported for other moonlighting
proteins, PGK can be found in supernatants, although the
precise mechanism of secretion and surface exposure of
this molecule remains unclear. Another similarity with the
moonlighting proteins is the ability to bind PLG. Interestingly,
in addition to PLG, PGK interacts simultaneously with tissue
plasminogen activator – tPA (Fulde et al., 2014), which
is responsible for PLG conversion into plasmin, leading to
degradation of extracellular matrix proteins and contributing
to bacterial invasion and dissemination, while hindering the
opsonic effect of the complement system (Fulde et al.,
2014).
Furthermore, PKG has recently been reported to bind ionically
and simultaneously to MAC proteins (Blom et al., 2014).
Pneumococcal MAC-mediated killing, as occurs with other
Gram-positive microbes, is found to be ineffective, due to an
increased resistance to insertion of C5b9 in the membrane
protected by a thick peptidoglycan (Blom et al., 2014). The
components of the terminal pathway C5, C7, and C9 were found
to interact with PKG, undermining MAC assembly as a result
of complement components depletion. Indeed, PGK associated
with the pneumococcal surface promoted an inhibition of MAC
deposition. These interactions were also able to reduce the
hemolytic capacity of human serum against the bacterium.
Moreover, PLG bound to PGK was activated in PL, which
cleaved C3b (Blom et al., 2014). The impaired assembly of MAC
takes place during the initial (by binding C5 and C7) and late
phases (by binding C9) of the terminal pathway. The binding
domains of C5 and C7 appear to be partially superimposed,
while the C9 site in PGK is not; this latter interaction is
capable of inhibiting the C9 self-polymerization (Blom et al.,
2014).
In summary, the many sites of interaction between PGK and
complement proteins suggest a role in pneumococcal ability to
avoid complement attack, since complement proteins interacting
with PGK ultimately become unavailable to participate in the
cascade.
Elongating factor Tu (Tufsp)
The elongating factor Tufsp is a surface-accessible protein
from S. pneumoniae, also found in the bacterial cytoplasm
and culture supernatants. It is a conserved protein found in
different species of bacteria and fungi, including pathogenic
and non-pathogenic organisms (Jacobson and Rosenbusch,
1976; Crowe et al., 2003; Archambaud et al., 2005; Gross
and Kinzy, 2005; Jonak, 2007; Li et al., 2013; Mohan et al.,
2014). Tuf exhibits molecular chaperone activity, being involved
in peptide biosynthesis, protein folding and cell response to
stress, promoting protein renaturation (Gregersen and Bross,
2010). It is also involved in the transport of amino-acyl-
tRNA to ribosomes (Murase et al., 2003; Nilsson and Nissen,
2005).
Pneumococcal Tuf was described by Mohan and co-workers as
a factor H-binding protein, identified through mass spectrometry
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of a gel band from a mutant pneumococcus lacking PspC,
which still reacted with Factor H by western blot (Mohan et al.,
2014). The domains of FH responsible for the interaction were
CCP 6–7 and 18–20 (heparin site). Tuf was also able to bind
to other complement regulators, FHL-1 (a short form of FH)
and to Factor H related protein 1 (CFHR-1) (CCP 3–5). The
complement regulatory activity promoted by FH and FHL-1
as cofactors of FI was maintained when they were bound to
Tuf. Moreover, the concomitant binding of Tuf and FH to
plasminogen promotes plasmin formation in presence of uPA,
which in turn cleaves fibrinogen, C3 and C3b (Mohan et al.,
2014). The combined effects of complement inhibition and
degradation of ECM components promoted by interaction of Tuf
with its many ligands enhance the bacterium’s ability to invade
host tissues.
COMPLEMENT-INTERACTING
PNEUMOCOCCAL PROTEINS AS
VACCINES CANDIDATES
The efficacy of the polysaccharide-based vaccines is attributed to
their ability to induce serotype-specific antibodies that promote
bacterial phagocytosis, a mechanism that is largely dependent on
complement activation (Song et al., 2013). This result reinforces
the importance of the complement system to vaccine-induced
protection against pneumococcal infection.
Several pneumococcal proteins have been investigated as
potential candidates for inclusion in a future pneumococcal
vaccine, with encouraging results (Hamel et al., 2004; Gor et al.,
2005; Gianfaldoni et al., 2007; Ferreira et al., 2009; Godfroid et al.,
2011; Hernani Mde et al., 2011; Kamtchoua et al., 2013; Darrieux
et al., 2015). PspA, PspC, Phts, NanA, PLY, RrgA, LytA, and
GAPDH have all been demonstrated to induce protection against
systemic infection [reviewed in (Darrieux et al., 2015) and (Miyaji
et al., 2013)]; PspC, Phts, NanA, and PspA were also protective
against nasopharyngeal colonization (Arulanandam et al., 2001;
Balachandran et al., 2002; Tong et al., 2005; Hernani Mde et al.,
2011), while NanA protects chinchillas against otitis media (Long
et al., 2004).
Moreover, the role of complement activation as a protective
mechanism promoted by vaccination has been exploited in
many studies, including animal models of colonization and
invasive disease (Darrieux et al., 2007, 2015; Ogunniyi et al.,
2007; Ferreira et al., 2010; Moreno et al., 2010; Paton, 2011;
Miyaji et al., 2013). The surface association or microbial
release of these proteins further supports their potential as
vaccine candidates, allowing immune recognition in vaccinated
individuals upon contact with the pathogen. Finally, PspA, PspC,
Phts, and Pds (derived from genetically or chemically detoxified
PLY) have also been evaluated in clinical trials, and shown
to be immunogenic and safe [reviewed in (Darrieux et al.,
2015)].
In order to improve vaccine immunogenicity and coverage,
combinations of these antigens have been used, with promising
outcomes. PspA and PspC have been shown to confer broad
protection against colonization and invasive diseases (Ferreira
et al., 2009). The inclusion of Phts also promotes potent
and protective immune responses. PspA and Pds were able
to augment protection against lethal pneumococcal sepsis
(Briles et al., 2000). Furthermore, the genetic fusion of
pneumococcal antigens has been employed as an alternative
strategy to broaden vaccine coverage, while reducing steps in
the production process. This is particularly important when
considering structurally variable antigens – such as PspA
(which is the most promising vaccine candidate so far, but
exhibits serological diversity which limits vaccine coverage).
In the case of PspA, genetic fusion of molecules from
different families (Darrieux et al., 2007), or fusion with Pds
(Goulart et al., 2013), showed an enhancement in vaccine
coverage.
CONCLUSION
The high numbers of pneumococcal proteins which are capable
of interacting with the complement system highlight the
importance of this defense mechanism to limit the diseases
caused by this pathogen. Many of these proteins act on the same
step of the complement cascade; this redundancy suggests that
the loss of one antigen may be compensated by another protein
with similar functions.
Several pneumococcal proteins have been evaluated as
potential vaccine candidates, with variable outcomes. The
emerging concept regarding protein-based pneumococcal
vaccines (which has been expanded to other pathogenic
bacteria and protozoa) is that the use of one protein alone
may not be sufficient to provide long term, wide protection
against pneumococcal diseases [reviewed in (Darrieux et al.,
2015)]. Therefore, the inclusion of different antigens in a
multi-component vaccine formulation has been emphasized
as a promising approach to prevent pneumococcal diseases.
In this sense, the combination of antigens that act over
the same mechanism may be an effective strategy to block
immune evasion by the pathogen, allowing for rapid bacterial
clearance. Therefore, we suggest that the combination of
pneumococcal proteins that act by limiting complement
activation on S. pneumoniae could provide strong protection
against infections caused by this pathogen. In particular, different
combinations of PspA, PspC, Phts e PLY (up to three proteins
in one formulation) have already been successfully evaluated
in animal models and clinical trials. However, the inclusion
of high numbers of antigens in a single formulation raises
concerns regarding protein interference, and also imposes
production limitations. An alternative would be the use of
protein chimeras – including immunogenic fragments of the
virulence factors genetically fused – which have been shown
to preserve individual antigenic properties and even expose
previously cryptic epitopes, while increasing vaccine coverage.
This would allow the inclusion of new vaccine candidates –
such as the moonlighting proteins – which can further enhance
vaccine efficacy. Nevertheless, more studies are needed in
order to determine the protective potential of this vaccine
approach.
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